Uncategorized
Sustained-release therapies remove patient factor from glaucoma treatment
Sustained delivery devices that take glaucoma therapy out of patients’ hands may be the answer to the many issues related to adherence, with significant benefits for patients and physicians.Not yet available on the U.S. market, these technologies fall under the broad category of guided administration of pharmaceuticals (GAP), ranging from injectable sustained-release formulations, to drug-eluting rings and contact lenses, to punctal plug reservoirs. Many are in the pipeline, undergoing phase 2 or nearing phase 3 trials.